Revance Fails Phase 3 Trial; Shares Down 24% In After-Hours
June 14, 2016 at 04:10 AM EDT
The phase 3 trial was using the company's drug RT001 to treat patients with lateral canthal lines, or Crows Feet. The drug in question is a topical gel that would be easier to administer in areas of the body that are very sensitive.
